EUVIMEDEUVIMED entdecken
Crossref

Radiomic biomarkers for platinum‐refractory head and neck cancer in the era of immunotherapy

Hsueh-Ju Lu iD, Chao-Yu Shen, Yu-Wei Chiu, Wea-Lung Lin, Chih-Yu Peng, Hsien-Chun Tseng, Chung-Han Hsin, Chun-Yi Chuang, Chun-Chia Chen, Ming-Fang Wu, Wei-Shiou Huang, Wei-Chih Shen

Oral Diseases · 2024

DOI: 10.1111/odi.14854 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oral Diseases, 2024. Verfasst von Hsueh-Ju Lu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Immune Checkpoint Inhibitors, Head and Neck Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Immune checkpoint inhibitors (ICI) are recommended as the first‐line therapy for platinum‐refractory head and neck squamous cell carcinoma (HNSCC), a disease with a poor prognosis. However, biomarkers in this situation are rare. The objective was to identify radiomic features‐associated biomarkers to guide the prognosis and treatment opinions in the era of ICI.

Methods

A total of 31 platinum‐refractory HNSCC patients were retrospectively enrolled. Of these, 65.5% (20/31) received ICI‐based therapy and 35.5% (11/31) did not. Radiomic features of the primary site at the onset of recurrent metastatic (R/M) status were extracted. Prognostic and predictive radiomic biomarkers were analysed.

Results

The median overall survival from R/M status (R/M OS) was 9.6 months. Grey‐level co‐occurrence matrix‐associated texture features were the most important in identifying the patients with or without 9‐month R/M death. A radiomic risk‐stratification model was established and equally separated the patients into high‐, intermittent‐ and lower‐risk groups (1‐year R/M death rate, 100.0% vs. 70.8% vs. 27.1%, p = 0.001). Short‐run high grey‐level emphasis (SRHGE) was more suitable than programmed death ligand 1 (PD‐L1) expression in selecting whether patients received ICI‐based therapy.

Conclusions

Radiomic features were effective prognostic and predictive biomarkers. Future studies are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Squamous Cell Carcinoma of Head and NeckImmune Checkpoint InhibitorsHead and Neck NeoplasmsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesBiomarkers, TumorPrognosisImmunotherapyDrug Resistance, NeoplasmAdultAged, 80 and overB7-H1 AntigenRadiomics

Stichwörter der Autor:innen

biomarkershead and neck squamous cell carcinomaimmune checkpoint therapyplatinum‐refractoryradiomic features

Substanzen

Immune Checkpoint InhibitorsBiomarkers, TumorB7-H1 Antigen

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • College of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • Department of Medical Imaging, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • Department of Stomatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • College of Oral Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • Department of Pathology, Chung Shan Medical University and Hospital, Taichung, Taiwan.

ORCID-Profile: Hsueh-Ju Lu

Zitieren

APA

Lu, H. J., Shen, C. Y., Chiu, Y. W., Lin, W. L., Peng, C. Y., Tseng, H. C., Hsin, C. H., Chuang, C. Y., Chen, C. C., Wu, M. F., Huang, W. S., & Shen, W. C. (2024). Radiomic biomarkers for platinum‐refractory head and neck cancer in the era of immunotherapy. Oral Diseases. https://doi.org/10.1111/odi.14854

Vancouver

Lu HJ, Shen CY, Chiu YW, Lin WL, Peng CY, Tseng HC, et al. Radiomic biomarkers for platinum‐refractory head and neck cancer in the era of immunotherapy. Oral Diseases. 2024. doi:10.1111/odi.14854

BibTeX
@article{Lu2024,
  author = {Lu, Hsueh-Ju and Shen, Chao-Yu and Chiu, Yu-Wei and Lin, Wea-Lung and Peng, Chih-Yu and Tseng, Hsien-Chun and Hsin, Chung-Han and Chuang, Chun-Yi and Chen, Chun-Chia and Wu, Ming-Fang and Huang, Wei-Shiou and Shen, Wei-Chih},
  title = {Radiomic biomarkers for platinum‐refractory head and neck cancer in the era of immunotherapy},
  journal = {Oral Diseases},
  year = {2024},
  doi = {10.1111/odi.14854}
}
Kostenlos starten →